<?xml version='1.0' encoding='utf-8'?>
<document id="23381958"><sentence text="Drug-drug interaction study of ACT-178882, a new renin inhibitor, and diltiazem in healthy subjects." /><sentence text="The cytochrome P450 (CYP) enzyme, CYP3A4, metabolizes ACT-178882, a new direct renin inhibitor" /><sentence text=" This study investigated the effect of diltiazem, a moderate inhibitor of CYP3A4, on the single-dose pharmacokinetics of ACT-178882 in healthy subjects" /><sentence text="" /><sentence text="In this open-label, two-way crossover, drug-drug interaction study, healthy young male subjects received treatments A and B in a randomized fashion" /><sentence text=" Treatment A consisted of a single dose of 100 mg ACT-178882 and treatment B of diltiazem 300 mg once a day for 13 days and a single dose of 100 mg ACT-178882 on day 4" /><sentence text=" Serial blood samples for the measurement of ACT-178882 were drawn pre-dose and up to 120 h post-dose during treatment A and pre-dose ACT-178882 and up to 240 h post-dose during treatment B" /><sentence text=" Trough blood samples for the measurement of diltiazem were taken on days 1-5 of dosing during treatment B" /><sentence text=" Safety was assessed by recording of vital signs and electrocardiogram, clinical laboratory tests and adverse event reporting" /><sentence text="" /><sentence text="Fourteen subjects were enrolled and completed the study" /><sentence text=" In the absence of diltiazem, the mean (95 % confidence interval [CI]) maximum concentration (Cmax) and area under the curve from time zero to infinity (AUC∞) were 26" /><sentence text="8 (20" /><sentence text="1-35" /><sentence text="8) ng/mL and 454 (351-587) ng·h/mL, respectively" /><sentence text=" In the presence of diltiazem these values were 43" /><sentence text="5 (36" /><sentence text="8-51" /><sentence text="4) ng/mL and 918 (781-1078) ng·h/mL, respectively" /><sentence text=" The median time to Cmax (tmax) for ACT-178882 was prolonged from 3" /><sentence text="5 to 5" /><sentence text="0 h by diltiazem whereas its apparent terminal half-life (t½) was unaffected by diltiazem, 22" /><sentence text="9 and 24" /><sentence text="2 h for treatments A and B, respectively" /><sentence text=" Using treatment A as reference, the geometric mean ratio (90 % CI) was 1" /><sentence text="62 (1" /><sentence text="36-1" /><sentence text="94) for Cmax and 2" /><sentence text="02 (1" /><sentence text="75-2" /><sentence text="34) for AUC∞, indicating a significant interaction between ACT-178882 and diltiazem" /><sentence text=" One (7" /><sentence text="1 %) and 3 (21" /><sentence text="3 %) of 14 subjects reported an adverse event during treatment A and B, respectively, with headache being the most frequently reported, with three events" /><sentence text=" There were no clinically relevant effects of treatments on vital signs, electrocardiogram or clinical laboratory variables" /><sentence text="" /><sentence text="Concomitant administration of diltiazem doubled the exposure to ACT-178882 without affecting t½" /><sentence text=" The clinical significance of this increase is at present unknown and will need to be investigated in future clinical studies" /><sentence text=" Treatment with ACT-178882 alone or in combination with diltiazem was safe and well tolerated" /><sentence text="" /></document>